Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
Sponsor: British Columbia Cancer Agency
Summary
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent implantation of radioactive seeds (the current standard of care in BC) and high dose rate (HDR) or temporary brachytherapy which is also available as a standard of care in BC but only when used as a boost in addition with external beam radiotherapy. In addition, men will be offered the opportunity for testing the aggressiveness of their cancer using Cell Cycle Progression Gene Profile.
Official title: A Phase III Randomized Pilot Study of Low Dose Rate Compared to High Dose Rate Prostate Brachytherapy for Favourable Risk and Low Tier Intermediate Risk Prostate Cancer
Key Details
Gender
MALE
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2016-05
Completion Date
2026-04
Last Updated
2025-03-13
Healthy Volunteers
No
Conditions
Interventions
Low dose rate prostate brachytherapy
Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
High Dose Rate prostate brachytherapy
Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
Locations (1)
British Columbia Cancer Agency Center for the Southern Interior
Kelowna, British Columbia, Canada